Medicine and Dentistry
Acute B-Cell Lymphoblastic Leukemia
21%
Acute Lymphoblastic Leukemia
31%
Adjuvant Therapy
21%
Amino Terminal Sequence
21%
Anemia
72%
Brain Natriuretic Peptide
21%
Cancer
24%
Chemotherapy-Induced Nausea and Vomiting
21%
Childhood Cancer
42%
Chronic Disease
21%
Chronic Kidney Disease
21%
Cross Sectional Study
25%
Diseases
24%
End Stage Renal Disease
21%
Family Functioning
21%
Ferritin
25%
Heart Hemosiderosis
21%
Hemodialysis
21%
Hepcidin
21%
Hypochromic Anemia
72%
Iron
90%
Iron Deficiency
73%
Iron Depletion
16%
Iron Overload
37%
Iron Supplement
21%
Ischemic Heart Disease
21%
Low Drug Dose
21%
Magnetic Resonance Imaging
15%
Malignant Neoplasm
68%
Multiplex Ligation Dependent Probe Amplification
21%
Nausea and Vomiting
21%
Pediatric Cancer
63%
Pediatric Quality of Life Inventory
24%
Pediatrics
66%
Pediatrics Patient
31%
Prematurity
21%
Prevalence
31%
Prognostic Factor
21%
QT Prolongation
21%
QTc Interval
21%
Quality of Life
63%
Randomized Controlled Trial
46%
Retching
17%
Reticulocyte
45%
Socioeconomic Status
21%
Symptomatic Treatment
47%
T Cell
21%
Thalassemia Major
42%
Treatment Group
16%
Zusanli
21%
Keyphrases
Acute Lymphoblastic Leukemia
58%
Anemia
28%
Anemia in children
42%
Anemia of Chronic Kidney Disease
21%
Anemia Prevalence
25%
Cardiac Iron Overload
25%
Chemotherapy
25%
Chemotherapy-induced Nausea
21%
Childhood Acute Lymphoblastic Leukemia
23%
Childhood Cancer
23%
Children with Cancer
57%
Chronic Kidney Disease in children
21%
Coronary Artery Disease
21%
Corrected QT Interval Prolongation
21%
Corticosteroid Injection
21%
Developing Countries
22%
Developing Country Perspective
21%
Disease-related Malnutrition
21%
Ferritin
30%
High-dose Corticosteroids
21%
Home Visits
24%
Home-based
21%
Hypertension
24%
Indonesia
24%
Induction Period
32%
Intravenous Iron
21%
Iron Deficiency
80%
Iron Deficiency Anemia
93%
Iron Profile
46%
Iron Status
36%
L-asparaginase
21%
Malignancy
21%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
21%
Pada
21%
Palliative Care
23%
Palliative Interventions
25%
Parental History
21%
Patients with Chronic Diseases
21%
Pediatric Cancer Patients
42%
Pediatric Palliative Care
21%
Pediatric Patients
26%
Premature Coronary Heart Disease
21%
Prognostic Factors
21%
Quality of Life
63%
Randomized Controlled Trial
45%
Renal Infiltration
21%
Reticulocyte Hemoglobin Content
66%
Risk Factors
24%
Screening Scale
21%
β-Thalassemia (β-thal)
42%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Lymphoblastic Leukemia
42%
Amino Terminal Pro Brain Natriuretic Peptide
5%
Anemia
70%
Asparaginase
21%
Biological Marker
12%
Brain Natriuretic Peptide
21%
Chemotherapy
27%
Chemotherapy Induced Nausea and Vomiting
21%
Childhood Cancer
21%
Chronic Disease
27%
Chronic Kidney Failure
21%
Clinical Trial
7%
Congestive Heart Failure
5%
Cross-Sectional Study
14%
Dexamethasone
12%
Diastolic Dysfunction
10%
Disease Marker
5%
Diseases
21%
End Stage Renal Disease
21%
Ferritin
18%
Heart Hemosiderosis
21%
Hemodialysis
21%
Hemosiderosis
5%
Hepcidin
21%
Hyperglycemia
21%
Hyperlipidemia
7%
Iron
100%
Iron Deficiency
53%
Iron Deficiency Anemia
47%
Iron Poisoning
37%
Ischemic Heart Disease
21%
Maintenance Dose
21%
Malignant Neoplasm
31%
Midazolam
21%
Myocardial Disease
13%
Nausea and Vomiting
15%
Prednisone
9%
Prematurity
21%
Prevalence
30%
QT Prolongation
21%
Retching
13%
Side Effect
7%
Thalassemia Major
42%
Transferrin
9%
Treatment Group
13%
Zusanli
21%